Author

C. Michener

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

O. Reizes· 3 shared C. Braley· 2 shared L. Chambers· 2 shared A. B. Nagaraj· 1 shared A. Chumakova· 1 shared A. DiFeo· 1 shared A. Hajjar· 1 shared A. Jarrar· 1 shared

Activity by Year

2017-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

O. Reizes

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy

L. Chambers, E. L. Esakov, C. Braley, L. Trestan, Z. Alali, D. Bayik, J. Lathia, N. Sangwan, P. Bazeley, A. S. Joehlin-Price, M. Dwidar, A. Hajjar, P. P. Ahern, J. Claesen, P. Rose, , O. Reizes

This study shows that antibiotic treatment disrupts the gut microbiome, leading to increased resistance to cisplatin in ovarian cancer models.

bioRxiv · Jun 16, 2020 · PreprintCancer Biology

Use of Transabdominal Ultrasound for the Detection of Intra-Peritoneal Tumor Engraftment and Growth in Mouse Xenografts of Epithelial Ovarian Cancer

L. Chambers, E. Esakov, C. Braley, M. AlHilli, C. Michener, O. Reizes

This study evaluates transabdominal ultrasound (TAUS) for detecting intra-peritoneal tumor growth in mouse xenografts of epithelial ovarian cancer, showing it can detect tumors as small as 2 mm and as early as seven days post-injection.

bioRxiv · Jan 20, 2020Cancer Biology

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors

C. Saygin, A. Wiechert, V. S. Rao, R. Alluru, E. Connor, P. S. Thiagarajan, J. S. Hale, Y. Li, A. Chumakova, A. Jarrar, Y. Parker, D. J. Lindner, A. B. Nagaraj, J. J. Kim, A. DiFeo, , O. Reizes

This study identifies CD55 as a signaling hub that regulates self-renewal and cisplatin resistance in endometrioid tumors through distinct signaling pathways.

bioRxiv · Jun 27, 2017Cancer Biology